OverviewSuggest Edit

Versantis is a developer of liver disease therapeutics and diagnostics intended to provide the first drug capture platform for the treatment of life-threatening intoxications. The company's pharmaceutical services offer novel antidotes, that focus on treatment for acute-on-chronic liver failure (ACLF), support the affected organs (liver, kidneys, brain) and encourage liver regeneration, enabling ACLF patients to receive life-saving therapies.

HQZürich, CH


Versantis is headquartered in
Zürich, Switzerland

Location Map

Latest Updates

Employees (est.) (Feb 2020)6

Key People/Management at Versantis

Vincent Forster

Vincent Forster

CEO and Board Member
Meriam Kabbaj

Meriam Kabbaj

COO and Board Member
Sophie Biguenet

Sophie Biguenet

Peter Nicklin

Peter Nicklin

Chairman, Board Of Directors
Show more

Versantis Office Locations

Versantis has an office in Zürich
Zürich, CH (HQ)
Technoparkstrasse & 1
Show all (1)

Versantis Financials and Metrics

Summary Metrics

Founding Date


Versantis total Funding

$20.7 m

Versantis latest funding size

$16.11 m

Time since last funding

5 months ago

Versantis investors

Versantis's latest funding round in September 2019 was reported to be $16.1 m. In total, Versantis has raised $20.7 m
Show all financial metrics

Versantis Online and Social Media Presence

Embed Graph

Versantis Frequently Asked Questions

  • When was Versantis founded?

    Versantis was founded in 2015.

  • Who are Versantis key executives?

    Versantis's key executives are Vincent Forster, Meriam Kabbaj and Sophie Biguenet.

  • How many employees does Versantis have?

    Versantis has 6 employees.

  • Who are Versantis competitors?

    Competitors of Versantis include AlzeCure Pharma, Jubilant Radiopharma and Igyxos.

  • Where is Versantis headquarters?

    Versantis headquarters is located at Technoparkstrasse & 1, Zürich.

  • Where are Versantis offices?

    Versantis has an office in Zürich.

  • How many offices does Versantis have?

    Versantis has 1 office.